SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB

Aug 04, 2015, 13:00 ET from Levi & Korsinsky, LLP

NEW YORK, Aug. 4, 2015 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Biogen Inc. ("Biogen" or the "Company") (NASDAQGS: BIIB) for possible violations of federal securities laws. The investigation concerns whether Biogen and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.  On Friday, July 24, 2015, prior to the opening of the market, Biogen reported its second quarter 2015 financial results. Among other things, the Company lowered its prior revenue guidance based largely on lowered expectations for the growth of its main drug, TECFIDERA. On the announcement of this news, the share price of Biogen stock plunged more than $59, or approximately 15%, during premarket trading on July 24, 2015 – from a prior day's closing price of $385.05 to the opening price of $326.01. To obtain additional information, go to:

or contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor 
New York, NY 10004 
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171 

Logo -


SOURCE Levi & Korsinsky, LLP